natgillin/translations-raw huggingface dataset:
The invention thus conceived is susceptible of numerous modifications and variations, all of which are within the scope of the appended claims; moreover, all the details may be replaced with other technically equivalent elements. 
Takva koncepcija predmetnog izuma podložna je brojnim izmjenama i inačicama, a sve spadaju u opseg priloženih patentnih zahtjeva; štoviše, sve navedene pojedinosti mogu se zamijeniti drugim tehnički jednakovrijednim elementima.
The compound of any of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein D1 is an optionally substituted phenyl, wherein the optional substitution is halo, cyano, C1-C6 alkyl, C1-C6 branched alkyl, halogenated C1-C6 alkyl, hydroxyl, C1-C6 alkyloxy, amino, or C1-C6 alkylamino or an optionally substituted pyridyl, wherein the optional substitution is halo, cyano, C1-C6 alkyl, C1-C6 branched alkyl, halogenated C1-C6 alkyl, hydroxyl, C1-C6 alkyloxy, amino, or C1-C6 alkylamino. 
Tvar iz bilo kojeg od patentnih zahtjeva 1-5, ili njena farmaceutski prihvatljiva sol, pri čemu je D, opcionalno supstituirani fenil, pri čemu je opcionalna supstitucija halo, cijano, C;-Cg alkil, Ci-Cg razgranati alkil, halogenirani Ci-C4 alkil, hidroksil, C,-Cg alkoksi, amino, ili C,-Cg alkilamino ili opcionalno supstituirani piridil, pri čemu je opcionalna supstitucija halo, cijano, C,-Cg alkil, C;-Cg razgranati alkil, halogenirani C,-Cg alkil, hidroksil, C,-Cg alkoksi, amino, ili Ci-Cg alkilamino.
A method for down-regulating the biological function of a protein comprising contacting said protein with a non-naturally occurring molecule comprising at least one B-aggregating region exposed to the environment, present in said protein and fused to a moiety that prevents aggregation of said beta-aggregating region, wherein the method is not performed in humans or animals, wherein said molecule is obtainable by providing 
Postupak za podregulaciju biološke funkcije proteina naznačen time da se sastoji od kontakta navedenog proteina sa molekulom koja se ne javlja u prirodi koja sadrži barem jedno B-agregacijsko područje koje je izloženo okolini, nalazi se u navedenom proteinu i fuzionirano je na skupinu koja sprječava agregaciju navedenog beta- agregacijskog područja, pri čemu se postupak ne provodi na ljudima ili životinjama, pri čemu je navedena molekula dobivena tako da sadrži
reducing the compound according to formula (13), or salt thereof, to obtain the compound according formula (1), or salt thereof. 
HR P20161484 T1 c) redukcija spoja prema formuli (13) ili njegove soli, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol.
The method of claim 9 directed to the treatment of neuropathic pain. 
Spoj za primjenu iz patentnog zahtjeva 9 usmjeren na liječenje neuropatske boli.
Easy reclosing system for a container (1) of dry foodstuffs, said system comprising a first flap (2) and a second flap (3) designed to overlap partially to achieve the closure of the container (1),; 
HR P20130564 T1 PATENTNI ZAHTJEVI Lagani sustav ponovnog zatvaranja za spremnik (1) za suhe prehrambene proizvode, te navedeni sustav sadrži prvi zaklopac (2) i drugi zaklopac (3) koji su dizajnirani da se djelomično preklapaju kako bi se postiglo zatvaranje spremnika (1);
The dividing walls 29 function as a lightweight building element and separate in this case individual homes which are built in a row. 
Pregradni zidovi 29 se koriste kao lagani građevni elementi 1 odvajaju u ovom slučaju zasebne domove koji su građeni u nizu.
The compound of formula (1) wherein: 
L Spoj formule (1):
the antibody or antigen binding portion thereof is administered intravenously, intramuscularly, or subcutaneously to the subject; and/or 
protutijelo ili njegov dio za vezanje na antigen primjenjuje se na subjekta intravenski, intramuskularno ili subkutano; i/ili
A gene therapy vector for use in treating a subject having Huntington's disease or a subject genetically predisposed for Huntington's disease who does not yet show symptoms of Huntington's disease, wherein the vector mediates expression of a double stranded RNA comprising a first RNA sequence and a second RNA sequence wherein the first and second RNA sequence are substantially complementary, wherein the first RNA sequence has a sequence length of at least 19 nucleotides and is complementary to SEQ ID NO:1. 
Dvolančana RNA koja sadrži prvi RNA slijed i drugi RNA slijed, gdje su prvi i drugi RNA slijed uglavnom komplementarni, naznačena time što prvi RNA slijed ima duljinu slijeda od najmanje 19 nukleotida i komplementaran je SEQ ID NO. 1, gdje se prvi RNA slijed bira iz skupine koju čine SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6, te SEQ ID NO.7, te gdje navedena dvolančana RNA može smanjiti eksprimiranje gena za huntingtin.
A further embodiment of the present invention is an above compound of formula 1, for use as a medicament for the treatment of traumatic brain injury, abdominal aortic aneurism and Graft vs. 
Spoj formule 1 u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time, da se upotrebljava kao lijek za liječenje traumatske ozljede mozga, abdominalne aneurizme aorte i bolesti presadak protiv domaćina (GvHD - eng.
adding a brewer's yeast or a yeast mother or a mixture thereof to said thermoplastic polymer to obtain a final product containing the brewer's yeast or the yeast mother or the mixture thereof, and thereafter 
= dodatak pivskog kvasca ili kvasca ili mješavina tih dvaju spomenutim termoplastičnim polimerima za dobivanje završnog proizvoda koji sadrži pivski kvasac ili kvasac ili mješavinu tih dvaju, i
A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and a pharmaceutically acceptable carrier or exipient. The pharmaceutical composition of claim 2, further comprising at least one additional therapeutic agent. 
Farmaceutski sastav prema zahtjevu 1 koji sadrži spoj formule IIB, ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, gdje R13 je -(CH2)0-3CR17R18NR20R21, -(CH2)0-3CR17R18NR17C(O)NR20R21 ili -(CH2)1-3-R23.
is an alkyl group, an olefinic group, or an aromatic group; and and P2 are each hydroxyl protecting groups; 
R; je alkil skupina, olefin skupina ili aromatska skupina; i P,iP, su, svaki hidroksil zaštitna skupina;
The pharmaceutical composition of Claim 11 or 12, wherein the bacterial infection is Clostridium difficile infection. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 11 ili 12, naznačen time što je bakterijska infekcija infekcija bakterijom Clostridium difficile.
represents hydrogen, fluorine or methoxy and 
R* predstavlja vodik, fluor ili metoksi i
that disperses both carbon black and solid filling materials and consists of highly polar, proton acceptor (N, O containing) compounds, 
- <okoja se sastoji od visoko polarnih spojeva sa akceptorom protonskih (koje sadrže N, O) skupina koje dispergiraju i čađu i čvrsta punila;
Coupled to this main action is the delayed action of the detaching means for the upper jaw and the lower jaw, respectively. 
Na to glavno djelovanje je povezano zakašnjelo djelovanje sredstva za odvajanje za gornju odnosno za donju čeljust.
The invention furthermore relates to a nucleic acid, which codes for a protein or polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 12-14, and 146-150, a part or derivative thereof. 
Primjena prema zahtjevu 6 ili 7, pri čemu antigen povezan s tumorom sadrži aminokiselinsku sekvencu izabranu iz grupe koja se sastoji od SEQ ID NOs: 16-19, 112, 113, 116, 1371 142-145.
Energy efficient system and process for treating sludge 
ENERGETSKI UČINKOVIT POSTUPAK ZA OBRADU MULJA
A method according to claim 5 wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler. 
Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se primjena provodi putem dozatora za medikament koji se bira između inhalatora sa spremnikom suhog praha, višedoznog inhalatora sa suhim prahom ili inhalatora za odmjerene doze.
The N-heterocyclic substances according to the present invention preferably exhibit a water solubility of at least 10 mg/kg, more preferably of at least 100 mg/kg. 
N-heterocikličke tvari prema ovom izumu poželjno pokazuju topljivost u vodi od najmanje 10 mg/kg, poželjnije od najmanje 100 mg/kg.
A method of generating rotation about an output axis (11), the method comprising: 
T) Generiranje rotacijskog kretanja oko izlazne osi (11), naznačen time, da se postupak sastoji od:
a time base circuit (106) that delivers time clock information (CLK) to the microcontroller (104), 
- < vremenskog kruga (106) koji mikrokontroleru (104) predaje vremenske informacije sata (CLK),
about 35% of the FVIII portion of the chimeric polypeptide is single chain FVIII and about 65% of the FVIII portion of the chimeric polypeptide is processed FVIII, or 40% of the FVIII portion of the chimeric polypeptide is single chain FVIII and 60% of the FVIII portion of the chimeric polypeptide is processed FVIII. 
Farmaceutski pripravak prema zahtjevu 1, naznačen time što (a) 25% FVIII dijela kimernog polipeptida je jednolančani FVIII i 75% FVIII dijela kimernog polipeptida je obrađeni FVIII, (b) 20% FVIII dijela kimernog polipeptida je jednolančani FVIII i 80% FVIII dijela kimernog polipeptida je obrađeni FVIII, ili (c) 15% FVIII dijela kimernog polipeptida je jednolančani FVIII i 85% FVIII dijela kimernog polipeptida je obrađeni FVIII.
The method for processing grass or hay according to claim 1, wherein following the screening and/or sifting of the grass or hay, a predefined fraction is removed and packed away in a filling unit. 
Postupak obrade trave ili sijena u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što nakon probiranja i/ili prosijavanja trave ili sijena, određenu frakciju, osobito grubu frakciju, se ukloni i po mogućnosti pakira zasebno u postaji za punjenje.
The mixture containing the 2 and 4-triazolyl-benzonitriles was purified by a combination of chromatography on silica gel (elution gradient of ethyl acetate in hexane) and on reversed phase silica gel to give 1.86 g (18% yield) of Intermediate 64 and 0.526 g (5% yield) of Intermediate 65. 
Smjesa koja sadrži 2 i 4-triazolil-benzonitrile je pročišćena kombiniranjem kromatografije na silika gelu (gradijent eluiranja od etil acetata u heksanu) i na reverzno faznom silika gelu da bi se dobilo 1.86 g (18 % prinos) Intermedijera 64 1 0.526 g (5 % prinos) Intermedijera 65.
• Phase H5) Calculation of the value Erich(if)n energy required in the node n in the interval (if); 
Faza H$) izračun vrijednosti Frich(1f), energije potrebne u čvoru n u intervalu (if);
The method according to claim 1, further comprising receiving a status of the handover request from the target cell with the highest weighted average of the RSRP values. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se dodatno sastoji u primanju stanja zahtjeva za prelazak 1z ciljane ćelije s najvišim ponderiranim prosjekom RSRP vrijednosti.
The device according to claim 1, wherein the perforated sheet comprises a plurality of triangular shaped holes. 
Uređaj sukladno zahtjevu 1, gdje perforirani list sadrži veći broj trokutasto oblikovanih rupa.
The liquefied gas treatment system according to claim 7, wherein the BOG supplied to the sub engine is BOG that is compressed while passing through all or part of the plurality of compression cylinders included in the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 4, naznačen time što otpareni plin poslan u izmjenjivač topline (21) je otpareni plin komprimiran prilikom prolaska kroz sve ili dio kompresijskih elemenata koje sadrži kompresor (13,13,13b).
Said coating system may has a coating device that applies said coating to each of the carrier substrates, and wherein said coating device is chosen from the group consisting of a first pad-printing device or a spraying device. 
Uređaj (10) u skladu s patentnim zahtjevom 8, naznačen time što navedeni sustav za oblaganje (600) ima napravu za prskanje koja naprska navedena obloga (2300) na svaku od nosivih tableta (1000).
The solid oral extended release pharmaceutical dosage form of claim 78, wherein the composition comprises at least about 80 % (by wt) of polyethylene oxide. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da pripravak sadrži 8 mg hidromorfon hidroklorida, te najmanje oko 94 % (težinski) polietilen oksida.
an oxidation reaction to obtain: 
II. reakciji oksidacije čime se dobije:
is hydrogen, halogen, hydroxyl, carboxyl, C1-6alkyl, C3-8cycloalkyl or C1-6alkoxy, said C1-6alkyl, C3-8cycloalkyl and C1-6alkoxy can optionally be substituted by 1, 2, 3 or 4 substituents independently selected from the group consisting of: halogen, hydroxyl, carboxyl and amino; 
je vodik, halogen, hidroksil, karboksil, C1-6alkil, C3-8cikloalkil ili C1-6alkoksi, spomenuti C1-6alkil, C3-8cikloalkil i C1-6alkoksi mogu izborno biti supstituirani s 1, 2, 3 ili 4 supstituenta nezavisno odabranih iz skupine koja se sastoji od: halogena, hidroksila, karboksila i amino;
A high purity diaminophenothiazinium compound according to claim 3, which is obtained by a method of synthesis comprising the steps of: nitrosylation, in which an N,N-disubstituted-3-optionally substituted aniline, 1, is 4-nitrosylated to give said N,N-disubstituted-3-optionally substituted-4-nitrosyl aniline, 2: 
Diaminofenotiazinski spoj visoke čistoće prema zahtjevu 2 ili 3, naznačen time, da se može dobiti putem postupka sinteze koji obuhvaća sljedeće korake, po redu: nitrozilacija (NOS) u kojoj se N,N-disupstituirani-3-opcionalno supstituirani anilin, 1, 4-nitrozilira kako bi dobio navedeni N,N-disupstituirani-3-opcionalno supstituirani-4-nitrozil-anilin, 2:
Valve according to claim 10, when dependent on claim 3, wherein said clearance is in a parallel plane with respect to, or coincident with, the one of said two zones. 
Ventil (10) u skladu s patentnim zahtjevom 9, kada je isti zavisan o patentnom zahtjevu 2, pri čemu je navedeni razmak (zazor) u paralelnoj ravnini u odnosu na, ili pak podudaran s jednom od navedene dvije zone (14a, 14 b).
a cold slurry viscosity as determined according to Method 1 as described on pages 6 to 7 of the description; of no more than 250 mPa.s; 
(i) - viskoznost hladne tekuće žbuke kao što je određeno Postupkom 1, kao što je opisano na stranicama 6 do 7 opisa izuma; od najviše 250 mPa.s;
The casting belt according to claim 12, wherein the casting belt (12, 14) is made from an alloy selected from AA5754, AA5052 and AA6061. 
Remen za lijevanje prema zahtjevu 12, naznačen time da je remen za lijevanje (12, 14) napravljen od legure odabrane od AA5754, AA5052 i AA6061. tr>
4) for thermal control of the refrigerated space 21, and for the sub-system 7 A to be independent of, but in communication with, the processing system 7 . In this way, even if the processing system 7 has problems, the thermal control is maintained; this is very useful for safeguarding the contents of the blood bags. To increase further the reliability of the apparatus 1 it is advantageous to provide for the sub-system 7 A an emergency power supply (for example a battery); this is very useful to keep safe the blood bags. 
Da bi se povećala pouzdanost ovog uredaja 1, poželjno je osigurati da sustav za obradu 7 sadržava podsustav 7A (vidi sliku 4) za toplinski nadzor prostora koji se hladi 21, i da podsustav 7A bude neovisan o sustavu za obradu 7, ali da bude u vezi s njim; na taj način, čak ako sustav za obradu 7 ima probleme, toplinski nadzor se održava; to je vrlo korisno za očuvanje sadržaja vrećica krvi. Da bi se još dalje povećala pouzdanost ovog uređaja 1, poželjno je osigurati da podsustav 7A bude opremljen s izvorom energije u slučaju opasnosti (na primjer, nekom baterijom); to je vrlo korisno za očuvanje sadržaja vrećica krvi.
The multiparticulate forms preferably have a size or size distribution in the range from 0.1 to 3 mm, particularly preferably in the range from 0.5 to 2 mm. 
Multipartikularni oblici imaju prvenstveno veličinu, odnosno raspodjelu veličine u području od 0,1 do 3 mm, osobito pogodno u području od 0,5 do 2 mm.
The process of embodiment 11, further comprising: 
Postupak u skladu s patentnim zahtjevom 11, nadalje sadrži:
Each sample was then diluted to a concentration of 1 mg/ml and used "as is" in the Ames assay. 
Svaki uzorak se tada razblaži do koncentracije 1 mg/ml i koristi se kao takav u Ames testu.
The telecommunications network (T) as claimed in claim 8 or 9, characterized in that the user data associated with a hash value are stored in the data node (DNDR), and the address, associated with a hash value, of that data node (DNDR) which holds the user data associated with the hash value, is stored in a localization node (DNLR). 
Telekomunikacijska mreža (T) temeljem zahtjeva 8 ili 9, naznačena time što se korisnički podaci povezani sa hash vrijednošću pohranjuju u podatkovnom čvorištu (DNDR), a adresa, povezana sa hash vrijednošću, tog podatkovnog čvorišta (DNDR) koja drži korisničke podatke povezane sa hash vrijednošću, je pohranjena u lokalizacijskom čvorištu (DNLR).
Tablets can be coated with a film coating comprising opacizers, colouring agents, plasticizers and flavouring agents. 
- < mikrokristalnu celulozu: 10.0-500.0 mg i proizvoljno je obložen s premazom filma koji sadržava sredstvo za postizanje neprozirnosti, plastifikator i bojilo.
The beverage containers 2 can be transported separately to the site of filling. 
Spremnik za piće 2 može se transportirati odvojeno do mjesta punjenja.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and component (B1) is selected from the group consisting of azoxystrobin and picoxystrobin. 
Pripravak prema zahijevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluoromelil-1-melil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, a kao komponentu (B) biksafen.
The pharmaceutical composition according to claim 1, wherein the coating agent is one or more species selected from the group consisting of hypromellose, ethyl cellulose, and polyvinyl alcohol. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je sredstvo za oblaganje jedna ili više vrsta koje se bira iz skupine koju čine hipromeloza, etilceluloza, te polivinil-alkohol.
A compressed pharmaceutical tablet or a direct compressed pharmaceutical tablet, wherein the dispersion contains particles comprising a DPP-IV inhibitor which is (S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine in free form or in acid addition salt form, and wherein at least 60% of the particle size distribution in the tablet is less than 250 µm. 
Direktno komprimirana farmaceutska tableta, naznačena time, da tablet obuhvaća sljedeće: a) od 22 do 28 masenih postotaka na bazi suhe mase inhibitora DPP-IV koji je (S)-1-[(3-hidroksi-1- adamantil)aminolacetil-2-cijanopirolidin u slobodnom obliku ili u obliku kiselinske adicijske soli; b) od 45 do 50 masenih postotaka na bazi suhe mase farmaceutski prihvatljive mikrokristalne celuloze;
Methods of treatment, and administration of the vaccine 
Broj objave europskog patenta:
Different embodiments include the following: A pharmaceutical composition comprising an effective amount of a compound of formula (I) and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži efikasnu količinu spoja prema patentnom zahtjevu 1 ili 2 ili njegove farmaceutski prihvatljive soli 1 farmaceutski prihvatljiv nosač.
A glassy lozenge according to claim 1 comprising (i) at least one gum, and (ii-a) at least one sugar and/or at least one sugar alcohol, wherein a major proportion of component (ii-a) consists of a non-crystallising mixture of sugars and/or sugar alcohols. 
Tableta-pastila prema patentnom zahtjevu 1, koja sadrži (i) najmanje jednu gumu, i (ii-a) najmanje jedan šećer i/ili najmanje jedan šećerni alkohol, naznačena time što se glavni dio komponente (ii-a) sastoji od ne-kristalizirajuće smjese šećera 1/ili šećernih alkohola.
The method of claim 19, wherein the antibodiy is the humanized anti-IL-6 receptor antibody MRA, and the formulation comprises 100 to 300 mg/ml of the antibody5 to 100 mM of a histidine buffering agent, and 0.005 to 3% (w/v) of polysorbate 80, and has a pH of 4 to 8, and wherein the arginine is added to the formulation in the amount of 50 to 700 mM, and the methionine in the amount of 10 to 100 mM. 
Postupak prema zahtjevu 19, naznačen time da protutijelo is humanizirano anti-IL-6 receptorsko protutijelo MRA, te formulacija sadrži 100 do 300 mg/ml protutijela 5 do 100 mM histidinskog puferskog sredstva, te 0.005 do 3% (t/v) polisorbata 80, te ima pH od 4 do 8, i pri čemu se arginin dodaje u formulaciju u količini od 50 do 700 mM, a metionin u količini od 10 do 100 mM.
X is hydrobromic acid, benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5-naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid; and 
X je bromovodična kiselina, benzensulfonska kiselina, kamfor sulfonska kiselina, 1,2-etan disulfonska kiselina, klorovodična kiselina, maleinska kiselina, metansulfonska kiselina, naftalen-2-sulfonska kiselina, 1,5-naftalen disulfonska kiselina, oksalna kiselina, 4-toluensulfonska kiselina ili 2,4,6-trihidroksibenzojeva kiselina.
The solid pharmaceutical composition of claim 1, further comprising an excipient selected from the group consisting of mannitol, xylitol, sorbitol, maltol, maltitol, lactose, sucrose, maltose, cyclodextrin, and combinations thereof. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 1, koja nadalje sadrži ekscipijens koji se bira iz skupine koju čine manitol, ksilitol, sorbitol, maltol, maltitol, laktoza, saharoza, maltoza, ciklodekstrin, i njihove kombinacije.
in response to the command received by the one or more servers, sending by the one or more servers the particular version of the particular data object from the first child set of data to the base set of data; 
sredstvo za stvaranje pregleda određenih podataka koji uključuje određene redove revizionirajuće baze podataka koji odgovaraju trećoj skupini podatkovnih objekata; i sredstvo za uzrokovanje prikazivanja pregleda određenih podataka prvom korisniku.
A process according to any one of claims 1 to 13, characterised in that the filling medium is not removed until the microfluidic arrangements (1) have been cleaned following mechanical machining. 
Postupak prema bilo kojem zahtjevu 1 do 13, naznačen time, da se punilo ne odstranjuje prije nego se mikrofluidne naprave (1) očiste nakon mehaničke strojne obrade.
is different from hydrogen; 
R" je drugačiji od vodika
The nasal cannula of claim 1, wherein the nasal cannula reduces delivery of nitrogen dioxide to the patient. 
Nosna kanila iz patentnog zahtjeva 1 ili 2, pri čemu je nosna kanila konfigurirana za minimiziranje dostave dušikovog oksida do pacijenta.
A compound according to any one of claims 1-15, or a pharmaceutically acceptable salt thereof for use in treating and/or preventing kidney injury and/or cardiovascular disease including hypertension, heart failure, myocardial infarction, angina pectoris, cardiac hypertrophy, myocarditis, cardiovascular fibrosis, baroceptor dysfunction, excess fluid and arhythmia, or endocrine disease, including primary/secondary aldosteronism, Addison's disease, Cushing's syndrome and Bartter's syndrome. 
Spoj prema bilo kojem od zahtjeva 1-15, ili njegova farmaceutski prihvatljiva sol za uporabu u liječenju i/ili prevenciji ozljede bubrega i/ili kardiovaskularne bolesti uključujući hipertenziju, zatajenje srca, miokardijalni infarkt, anginu pectoris, srčanu hipertrofiju, miokarditis, kardiovaskularnu fibrozu, baroceptorsku disfunkciju, višak fluida 1 aritmiju, ili endokrine bolesti, uključujući primarni/sekundarni aldosteronizam, Addisonovu bolest, Cushingov sindrom i Bartterov sindrom.